Cited 0 times in
The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 백용한 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2015-06-10T11:57:44Z | - |
dc.date.available | 2015-06-10T11:57:44Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/108936 | - |
dc.description.abstract | The early emergence of lamivudine (3TC)-resistant tyrosine-methionine-aspartate-aspartate (YMDD) mutants has been reported during 3TC therapy in patients with chronic hepatitis B (CHB) in hepatitis B virus (HBV)-endemic areas; however, its clinical impact during long-term 3TC therapy is unknown. This study was performed to investigate the impact of the early emergence of YMDD mutants 3 months after the initiation of treatment on the outcomes of long-term 3TC therapy in HBV e antigen (HBeAg)-positive CHB. We analysed YMDD genotypes in consecutive samples from 30 patients with HBeAg positive CHB throughout 3TC treatment using both restriction fragment length polymorphism and mass spectrometric assays. Long-term outcome was compared between patients who had YMDD mutations detected at 3 months and those who had no mutations. YMDD mutation was detected in 16 (53.3%) out of 30 patients at 3 months and only the rtM204I mutation was found. Cumulative HBeAg loss rates at 3 years was 12.5% and 57.4% in patients who had the rtM204I mutant and wild-type virus at 3 months, respectively (P=0.010). Cumulative viral breakthrough rates at 3 years was 75.0% and 14.3% in patients who had the rtM204I mutant and wild-type virus at 3 months, respectively (P=0.002). Logistic regression revealed that YMDD mutation at 3 months was significantly related to viral breakthrough within 24 months (P=0.003). In conclusion, early detection for HBV YMDD mutation at 3 months may be useful to predict the long-term outcomes of 3TC therapy in patients with HBeAg-positive CHB in HBV-endemic areas. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 447~455 | - |
dc.relation.isPartOf | ANTIVIRAL THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antiviral Agents/pharmacology | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Drug Resistance, Viral/genetics | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepatitis B e Antigens/blood | - |
dc.subject.MESH | Hepatitis B virus/drug effects | - |
dc.subject.MESH | Hepatitis B virus/enzymology | - |
dc.subject.MESH | Hepatitis B virus/genetics* | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis B, Chronic/virology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/pharmacology | - |
dc.subject.MESH | Lamivudine/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation* | - |
dc.subject.MESH | Polymorphism, Restriction Fragment Length | - |
dc.subject.MESH | RNA-Directed DNA Polymerase/genetics | - |
dc.subject.MESH | Reverse Transcriptase Inhibitors/pharmacology | - |
dc.subject.MESH | Reverse Transcriptase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yong-Han Paik | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Sun Pyo Hong | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.contributor.googleauthor | Soo-Ok Kim | - |
dc.contributor.googleauthor | Ji Eun Shin | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Chae Yoon Chon | - |
dc.contributor.googleauthor | Young Myoung Moon | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01829 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A03544 | - |
dc.relation.journalcode | J00191 | - |
dc.identifier.eissn | 2040-2058 | - |
dc.identifier.pmid | 16856618 | - |
dc.identifier.url | http://www.intmedpress.com/journals/avt/abstract.cfm?id=567&pid=88 | - |
dc.contributor.alternativeName | Paik, Yong Han | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Kwan Sik | - |
dc.contributor.alternativeName | Chon, Chae Yoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Paik, Yong Han | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Kwan Sik | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Chon, Chae Yoon | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 11 | - |
dc.citation.startPage | 447 | - |
dc.citation.endPage | 455 | - |
dc.identifier.bibliographicCitation | ANTIVIRAL THERAPY, Vol.11 : 447-455, 2006 | - |
dc.identifier.rimsid | 50351 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.